

## **ENZAR**

**For the use of a Registered Medical Practitioner or a Hospital or a Laboratory Only**

Abbreviated Prescribing information for **ENZAR** [Pancreatin Gastro Resistant Capsules B.P.]

[Please refer the complete prescribing information available at [www.torrentpharma.com](http://www.torrentpharma.com)]

### **PHARMACOLOGICAL PROPERTIES:**

**MECHANISM OF ACTION:** The capsules dissolve rapidly in the stomach releasing plenty of minimicrospheres, a multidose principle which is designed to achieve good mixing with the chyme, emptying from the stomach together with the chyme and after release, good distribution of enzymes within the chyme. When the minimicrospheres reach the small intestine the coating rapidly disintegrates (at pH > 5.5) to release enzymes with lipolytic, amylolytic and proteolytic activity to ensure the digestion of fats, starches and proteins. The products of pancreatic digestion are then either absorbed directly, or following further hydrolysis by intestinal enzymes.

**INDICATION:** It is indicated for treatment of patient with exocrine pancreatin enzyme insufficiency.

**DOSAGE AND ADMINISTRATION:** As directed by physician.

**CONTRAINDICATION:** Hypersensitivity to the active substance or to any of the excipients

**WARNINGS & PRECAUTIONS:** Strictures of the ileo-caecum and large bowel (fibrosing colonopathy) have been reported in patients with cystic fibrosis taking high doses of pancreatin preparations. As a precaution, unusual abdominal symptoms or changes in abdominal symptoms should be medically assessed to exclude the possibility of fibrosing colonopathy, especially if the patient is taking in excess of 10,000 units of lipase/kg/day.

**DRUG INTERACTIONS:** NA

**ADVERSE REACTIONS:** abdominal pain, nausea, vomiting, constipation, abdominal distention, diarrhea, strictures of the ileo-caecum and large bowel (fibrosing colonopathy), rash, pruritus, urticaria, hypersensitivity (anaphylactic reactions).

**MARKETED BY:**

**TORRENT**  
PHARMA

TORRENT PHARMACEUTICALS LTD.

**IN/ENZAR/FEB-2026/03/ABPI**

(Additional information is available on request)